---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031599"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:35:38.868185+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abeona Q3 net loss $9.5M; Phase 3 EB-101 meets endpoints, BLA submission planned Q2 2023

## Summary
- Net loss of $9.5M ($1.48 loss per share) for Q3 2022, compared to $7.0M loss in Q3 2021.
- Cash, equivalents and investments totaled $23.5M at Sept 30, 2022; subsequent $35M private placement extends runway into Q3 2024.
- Phase 3 VIITAL trial of EB-101 for RDEB met both co-primary endpoints with statistically significant wound healing and pain reduction.
- Company plans to submit BLA to FDA for EB-101 in Q2 2023; possible Priority Review Voucher eligibility upon approval.
- R&D expenses decreased to $5.5M from $9.1M year-over-year; G&A expenses down to $3.9M from $5.8M.

## SEC filing metadata
- accession: 0001493152-22-031599
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031599
- JSON: https://secwatch.observer/filing/0001493152-22-031599.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031599.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported third quarter of 2022 results: net income $9.5 million, EPS $1.48 loss per common share.
  - Period: third quarter of 2022
  - Net income: $9.5 million
  - EPS: $1.48 loss per common share
  - Result: reported results
  source text: Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.